Clonal distribution of BCR-ABL1 mutations and splice isoforms by single-molecule long-read RNA sequencing
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Clonal distribution of BCR-ABL1 mutations and splice isoforms by single-molecule long-read RNA sequencing ; volume:15 ; number:1 ; day:12 ; month:2 ; year:2015 ; pages:1-12 ; date:12.2015
BMC cancer ; 15, Heft 1 (12.2.2015), 1-12, 12.2015
- Urheber
-
Cavelier, Lucia
- Beteiligte Personen und Organisationen
-
Ameur, Adam
Häggqvist, Susana
Höijer, Ida
Cahill, Nicola
Olsson-Strömberg, Ulla
Hermanson, Monica
SpringerLink (Online service)
- DOI
-
10.1186/s12885-015-1046-y
- URN
-
urn:nbn:de:1111-2016110614809
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:53 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Cavelier, Lucia
- Ameur, Adam
- Häggqvist, Susana
- Höijer, Ida
- Cahill, Nicola
- Olsson-Strömberg, Ulla
- Hermanson, Monica
- SpringerLink (Online service)
Ähnliche Objekte (12)
The e13a3 (b2a3) and e14a3 (b3a3) BCR::ABL1 isoforms are resistant to asciminib
Genomische BCR-ABL1-Bruchpunkte bei kindlichen Leukämien
BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
FISH mapping of Philadelphia negative BCR/ABL1 positive CML
Approach to Diagnosis of BCR::ABL1-Negative Myeloproliferative Neoplasms
Analysis of transcripts and splice isoforms in red clover (Trifolium pratense L.) by single-molecule long-read sequencing
Targeting Poly(ADP)ribose polymerase in BCR/ABL1-positive cells
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1
Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy
Decrypting the role of HSP90α and β isoforms in BCR-ABL1+ leukemia and Characterization of Small Molecule HSP90 Inhibitors and Degraders
Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K
The role of proteostasis in BCR-ABL1-positive acute lymphoblastic leukemia
The e13a3 (b2a3) and e14a3 (b3a3) BCR::ABL1 isoforms are resistant to asciminib
Genomische BCR-ABL1-Bruchpunkte bei kindlichen Leukämien
BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
FISH mapping of Philadelphia negative BCR/ABL1 positive CML
Approach to Diagnosis of BCR::ABL1-Negative Myeloproliferative Neoplasms
Analysis of transcripts and splice isoforms in red clover (Trifolium pratense L.) by single-molecule long-read sequencing
Targeting Poly(ADP)ribose polymerase in BCR/ABL1-positive cells
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1
Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy
Decrypting the role of HSP90α and β isoforms in BCR-ABL1+ leukemia and Characterization of Small Molecule HSP90 Inhibitors and Degraders
Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K
The role of proteostasis in BCR-ABL1-positive acute lymphoblastic leukemia
The e13a3 (b2a3) and e14a3 (b3a3) BCR::ABL1 isoforms are resistant to asciminib
Genomische BCR-ABL1-Bruchpunkte bei kindlichen Leukämien
BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
FISH mapping of Philadelphia negative BCR/ABL1 positive CML
Approach to Diagnosis of BCR::ABL1-Negative Myeloproliferative Neoplasms
Analysis of transcripts and splice isoforms in red clover (Trifolium pratense L.) by single-molecule long-read sequencing
Targeting Poly(ADP)ribose polymerase in BCR/ABL1-positive cells
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1
Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy
Decrypting the role of HSP90α and β isoforms in BCR-ABL1+ leukemia and Characterization of Small Molecule HSP90 Inhibitors and Degraders
Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K